Quick Takeaways
- This page summarizes Barbara Gayle Duncan's Form 4 filing for Fusion Pharmaceuticals Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 22 Jun 2022, 19:07.
Barbara Gayle Duncan - 14 Jun 2022 Form 4 Insider Report for Fusion Pharmaceuticals Inc.
- Role
- Director
- Signature
- /s/Maria Stahl as Attorney-in-Fact for Barbara Duncan
- Issuer symbol
- N/A
- Transactions as of
- 14 Jun 2022
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 22 Jun 2022, 19:07:42 UTC
- Previous filing
- 12 Apr 2022
- Next filing
- 21 Jun 2022
- SEC
- View on sec.gov
Quoteable Key Fact
"Barbara Gayle Duncan filed Form 4 for Fusion Pharmaceuticals Inc. on 22 Jun 2022."
What Changed
- Previous filing in this sequence was filed on 12 Apr 2022.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | FUSN | Stock Opion (Right to Buy) | Award | $0 | +17,000 | $0.000000 | 17,000 | 14 Jun 2022 | Common Stock | 17,000 | $3.60 | Direct | F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | This option fully vests on the earlier of (i) June 14, 2023 or (ii) the 2023 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc. |